Allianz SE Sells 43,425 Shares of DexCom, Inc. $DXCM

Allianz SE trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 83.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 8,636 shares of the medical device company’s stock after selling 43,425 shares during the period. Allianz SE’s holdings in DexCom were worth $581,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Brighton Jones LLC increased its position in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC grew its stake in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the period. Empowered Funds LLC grew its stake in DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth increased its position in shares of DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC bought a new stake in shares of DexCom during the 2nd quarter worth $317,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 1.3%

Shares of DexCom stock opened at $73.43 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a market cap of $28.26 billion, a price-to-earnings ratio of 34.97, a PEG ratio of 1.43 and a beta of 1.49. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $70.24 and its 200-day moving average price is $69.15.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the company earned $0.45 earnings per share. DexCom’s revenue for the quarter was up 13.1% on a year-over-year basis. On average, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DXCM. Sanford C. Bernstein restated an “outperform” rating and set a $86.00 price target (up from $84.00) on shares of DexCom in a research report on Friday, January 9th. Mizuho boosted their target price on shares of DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Weiss Ratings downgraded shares of DexCom from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group set a $95.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Friday, February 13th. Finally, UBS Group reduced their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.18.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.